A Potent Recombinant Polyclonal Antibody Therapeutic for Protection Against New Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern

Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) possess mutations that prevent antibody therapeutics from maintaining antiviral binding and neutralizing efficacy. Monoclonal antibodies (mAbs) shown to neutralize Wuhan-Hu-1 SARS-CoV-2 (ancestral) strain have reduced...

Descripción completa

Detalles Bibliográficos
Autores principales: Wayham, Nicholas P, Niedecken, Ariel R, Simons, Jan Fredrik, Chiang, Yao Y, Medina-Cucurella, Angélica V, Mizrahi, Rena A, Wagner, Ellen K, Gras, Ashley, Segal, Ilana, Witte, Peyton, Enstrom, Alexis, Bountouvas, Aristea, Nelson, Sabrina M, Weinberger, Tess, Tan, David, Asensio, Michael A, Subramanian, Alagu, Lim, Yoong Wearn, Adler, Adam S, Keating, Sheila M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469345/
https://www.ncbi.nlm.nih.gov/pubmed/37062677
http://dx.doi.org/10.1093/infdis/jiad102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469345/
https://www.ncbi.nlm.nih.gov/pubmed/37062677
http://dx.doi.org/10.1093/infdis/jiad102

Ejemplares similares